Efficacy and Safety of Switching between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review.

Intern Med · 2025 · PMC12331329 · PMID 39756881

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In Patients 6 and 7, MMD remained the same 3 months after erenumab initiation; however, two patients who were responders at the 3-month time point showed an increasing trend in MMD thereafter (Patient 3: 14-23 MMD; Patient 4: 3-10 MMD).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.